As the Australian stock market experiences a modest rise amidst geopolitical uncertainties, investors are keeping a close watch on sectors poised for growth and resilience. In such an environment, companies with high insider ownership often attract attention due to the confidence they signal in their own potential, making them intriguing prospects for those seeking long-term growth opportunities.

Top 10 Growth Companies With High Insider Ownership In Australia

Name Insider Ownership Earnings Growth Torque Metals (ASX:TOR) 18.6% 94.2% Magnetic Resources (ASX:MAU) 33.6% 124.2% Forrestania Resources (ASX:FRS) 35.5% 102.3% Fenix Resources (ASX:FEX) 19.7% 62.5% Echo IQ (ASX:EIQ) 19.6% 109.4% Cyclopharm (ASX:CYC) 10.4% 117.1% Clinuvel Pharmaceuticals (ASX:CUV) 10.3% 27.1% Austral Resources Australia (ASX:AR1) 18.9% 39.1% Adveritas (ASX:AV1) 17.9% 109.9% Advanced Energy Minerals (ASX:AEM) 37.5% 48.4%

Click here to see the full list of 113 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

Let's dive into some prime choices out of the screener.

Echo IQ

Simply Wall St Growth Rating: ★★★★★★

Overview: Echo IQ Limited provides artificial intelligence diagnostics tools to improve the diagnosis of structural heart disease in Australia and has a market cap of A$589.12 million.

Operations: Echo IQ Limited generates revenue primarily from the development of artificial intelligence software, amounting to A$0.09 million.

Insider Ownership: 19.6%

Echo IQ, recently added to the S&P/ASX All Ordinaries Index, is forecasted for significant growth with expected annual revenue increases of over 120%, outpacing the Australian market. Although it currently reports less than A$91K in revenue and a net loss of A$8.66 million for the last half-year, its projected profitability within three years and high future return on equity highlight potential as a growth company despite current financial challenges.

Navigate through the intricacies of Echo IQ with our comprehensive analyst estimates report here. According our valuation report, there's an indication that Echo IQ's share price might be on the expensive side.ASX:EIQ Ownership Breakdown as at Mar 2026

Regis Healthcare

Simply Wall St Growth Rating: ★★★★★☆

Overview: Regis Healthcare Limited provides residential aged care services in Australia and has a market cap of A$1.98 billion.

Operations: The company generates revenue of A$1.26 billion from its residential aged care, home care, and retirement living services in Australia.

Insider Ownership: 38.6%

Regis Healthcare is positioned for growth, with insiders buying more shares than selling recently. Forecasted earnings growth of 23% annually outpaces the Australian market. Despite slower revenue growth at 8.7%, it exceeds market averages and supports strategic acquisitions and developments. Recent funding reforms and favorable demographics bolster its outlook, while a strong balance sheet aids expansion plans. The appointment of experienced healthcare executive Carmel Monaghan strengthens governance as Regis pursues long-term value creation for shareholders.

Story Continues

Click to explore a detailed breakdown of our findings in Regis Healthcare's earnings growth report. The analysis detailed in our Regis Healthcare valuation report hints at an deflated share price compared to its estimated value.ASX:REG Ownership Breakdown as at Mar 2026

Telix Pharmaceuticals

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company that develops and commercializes therapeutic and diagnostic radiopharmaceuticals, with a market cap of A$4.38 billion.

Operations: The company generates revenue from three primary segments: Therapeutics ($9.27 million), Precision Medicine ($621.93 million), and Manufacturing Solutions ($245.11 million).

Insider Ownership: 14.9%

Telix Pharmaceuticals is advancing its growth trajectory with significant insider ownership and strategic developments. The recent resubmission of the NDA for TLX101-Px to the FDA highlights its focus on addressing unmet medical needs in brain cancer imaging, supported by orphan drug and fast track designations. Although revenue growth is projected at 13.8% annually, slower than some peers, it surpasses market averages. Telix's profitability outlook within three years enhances its investment appeal amidst ongoing clinical advancements and regulatory pursuits.

Delve into the full analysis future growth report here for a deeper understanding of Telix Pharmaceuticals. Our comprehensive valuation report raises the possibility that Telix Pharmaceuticals is priced lower than what may be justified by its financials.ASX:TLX Earnings and Revenue Growth as at Mar 2026

Seize The Opportunity

Dive into all 113 of the Fast Growing ASX Companies With High Insider Ownership we have identified here. Want To Explore Some Alternatives? Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include ASX:EIQ ASX:REG and ASX:TLX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments